$APLT
Applied Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023018422 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $9.993M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.62M $4.710M
YoY Change 199.75% -24.52%
% of Gross Profit
Research & Development $53.91M $10.79M
YoY Change 345.79% -17.77%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $74.53M $15.50M
YoY Change 292.83% -19.95%
Operating Profit -$15.50M
YoY Change -19.95%
Interest Expense $1.372M $392.0K
YoY Change 406.27% 72.69%
% of Operating Profit
Other Income/Expense, Net -$56.60M -$26.88M
YoY Change -1424.91% -10639.22%
Pretax Income -$119.8M -$42.37M
YoY Change 730.02% 121.82%
Income Tax
% Of Pretax Income
Net Earnings -$119.8M -$42.37M
YoY Change 730.02% 121.82%
Net Earnings / Revenue -1198.47%
Basic Earnings Per Share -$0.47
Diluted Earnings Per Share -$1.42 -$0.47
COMMON SHARES
Basic Shares Outstanding 77.23M 63.12M
Diluted Shares Outstanding 90.67M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.15M $37.50M
YoY Change 64.0% -20.85%
Cash & Equivalents $49.90M $37.50M
Short-Term Investments $254.0K $0.00
Other Short-Term Assets $100.0K $837.0K
YoY Change -85.16% 38.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $54.39M $44.49M
YoY Change 45.78% -19.86%
LONG-TERM ASSETS
Property, Plant & Equipment $447.0K $500.0K
YoY Change -47.84% -48.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $200.0K
YoY Change -100.0% 0.5%
Total Long-Term Assets $447.0K $707.0K
YoY Change -57.63% -39.52%
TOTAL ASSETS
Total Short-Term Assets $54.39M $44.49M
Total Long-Term Assets $447.0K $707.0K
Total Assets $54.83M $45.20M
YoY Change 42.93% -20.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.742M $6.005M
YoY Change -61.58% -13.88%
Accrued Expenses $15.72M $12.70M
YoY Change 3.16% -11.46%
Deferred Revenue $667.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $71.18M $55.50M
YoY Change 112.97% 19.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $797.0K $700.0K
YoY Change -9.23% 30.6%
Total Long-Term Liabilities $797.0K $735.0K
YoY Change -9.23% 37.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $71.18M $55.50M
Total Long-Term Liabilities $797.0K $735.0K
Total Liabilities $71.98M $56.24M
YoY Change 109.84% 19.53%
SHAREHOLDERS EQUITY
Retained Earnings -$468.6M -$430.9M
YoY Change 34.35% 28.86%
Common Stock $8.000K $7.000K
YoY Change 60.0% 40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$17.15M -$11.04M
YoY Change
Total Liabilities & Shareholders Equity $54.83M $45.20M
YoY Change 42.93% -20.26%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$119.8M -$42.37M
YoY Change 730.02% 121.82%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$17.01M -$14.73M
YoY Change 7.0% -24.03%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $2.000K $0.00
YoY Change -100.03% -100.0%
Cash From Investing Activities $2.000K $0.00
YoY Change -100.03% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 29.45M 16.57M
YoY Change -3256.06% -1806.49%
NET CHANGE
Cash From Operating Activities -17.01M -14.73M
Cash From Investing Activities 2.000K 0.000
Cash From Financing Activities 29.45M 16.57M
Net Change In Cash 12.44M 1.840M
YoY Change -152.43% -111.99%
FREE CASH FLOW
Cash From Operating Activities -$17.01M -$14.73M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001697532
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
CY2023Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38898
dei Entity Registrant Name
EntityRegistrantName
Applied Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3405262
dei Entity Address Address Line1
EntityAddressAddressLine1
545 Fifth Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1400
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
220-9226
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
APLT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77229207
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37457000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16657000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
13923000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7031000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6728000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
44488000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
37308000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
510000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
857000
CY2023Q3 aplt Security Deposit And Leasehold Improvements Net
SecurityDepositAndLeaseholdImprovementsNet
197000
CY2022Q4 aplt Security Deposit And Leasehold Improvements Net
SecurityDepositAndLeaseholdImprovementsNet
198000
CY2023Q3 us-gaap Assets
Assets
45195000
CY2022Q4 us-gaap Assets
Assets
38363000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
491000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
477000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6005000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4534000
CY2023Q3 aplt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12245000
CY2022Q4 aplt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
14756000
CY2023Q3 aplt Warrant Liability Current
WarrantLiabilityCurrent
36763000
CY2022Q4 aplt Warrant Liability Current
WarrantLiabilityCurrent
13657000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
55504000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33424000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
414000
CY2023Q3 aplt Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
691000
CY2022Q4 aplt Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
464000
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
735000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
878000
CY2023Q3 us-gaap Liabilities
Liabilities
56239000
CY2022Q4 us-gaap Liabilities
Liabilities
34302000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77133516
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77133516
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48063358
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48063358
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
419856000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
352828000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
51000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-430907000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-348823000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-11044000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4061000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45195000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38363000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10660000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10660000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10785000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13116000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38602000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43542000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4710000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6240000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15585000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20436000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
15495000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
19356000
us-gaap Operating Expenses
OperatingExpenses
54187000
us-gaap Operating Expenses
OperatingExpenses
63978000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15495000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19356000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43527000
us-gaap Operating Income Loss
OperatingIncomeLoss
-63978000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
392000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
227000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1020000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
414000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
27277000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-36000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
39611000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4321000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-194000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26875000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
255000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-38557000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4101000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-42370000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19101000
us-gaap Net Income Loss
NetIncomeLoss
-82084000
us-gaap Net Income Loss
NetIncomeLoss
-68079000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42370000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-42370000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19101000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19101000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-82084000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-82084000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68079000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-68079000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.02
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90669969
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90669969
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48000183
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48000183
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75482234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75482234
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33785386
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33785386
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-42370000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19101000
us-gaap Net Income Loss
NetIncomeLoss
-82084000
us-gaap Net Income Loss
NetIncomeLoss
-68079000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
17000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-51000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
130000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
17000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-51000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
130000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42370000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19084000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-82135000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67949000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
62539000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2518000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23121000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
27000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
41963000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5968000
CY2022Q2 aplt Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
1417000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2231000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-25857000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
86000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
25808000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
49000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2856000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19101000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
17000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
9629000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4061000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2055000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10137000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-51000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4072000
CY2023Q2 aplt Stock Issued During Period Value Common Stock Pre Funded Warrants And Common Stock Warrants Sold For Cash
StockIssuedDuringPeriodValueCommonStockPreFundedWarrantsAndCommonStockWarrantsSoldForCash
27450000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1843000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29577000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4334000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7004000
CY2023Q3 aplt Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
26755000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1836000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-42370000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-11044000
us-gaap Profit Loss
ProfitLoss
-82084000
us-gaap Profit Loss
ProfitLoss
-68079000
us-gaap Share Based Compensation
ShareBasedCompensation
5734000
us-gaap Share Based Compensation
ShareBasedCompensation
7605000
aplt Amortization Of Insurance Premium
AmortizationOfInsurancePremium
1723000
aplt Amortization Of Insurance Premium
AmortizationOfInsurancePremium
2806000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
347000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
328000
aplt Amortization Of Leasehold Improvements
AmortizationOfLeaseholdImprovements
1000
aplt Amortization Of Leasehold Improvements
AmortizationOfLeaseholdImprovements
1000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-356000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-327000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
39611000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4321000
aplt Increase Decrease In Financed Insurance Premium
IncreaseDecreaseInFinancedInsurancePremium
1546000
aplt Increase Decrease In Financed Insurance Premium
IncreaseDecreaseInFinancedInsurancePremium
3105000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
480000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
262000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1471000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2488000
aplt Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
-2816000
aplt Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
-3000000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
227000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38168000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62200000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
36911000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
4944000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8928000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
56986000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13872000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20075000
aplt Proceeds From Issuance Of Shares And Pre Funded Warrants
ProceedsFromIssuanceOfSharesAndPreFundedWarrants
34606000
aplt Proceeds From Issuance Of Shares And Pre Funded Warrants
ProceedsFromIssuanceOfSharesAndPreFundedWarrants
27811000
aplt Proceeds From Financed Insurance Premium
ProceedsFromFinancedInsurancePremium
1546000
aplt Proceeds From Financed Insurance Premium
ProceedsFromFinancedInsurancePremium
3105000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1393000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
2340000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
87000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
49000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10250000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45096000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28625000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20800000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13500000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16657000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53888000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37457000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40388000
aplt Initial Measurement Of Warrant Liability
InitialMeasurementOfWarrantLiability
21835000
aplt Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
16505000
aplt Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
1417000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-51000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
130000
aplt Stock Issuance Costs In Accrued Expenses
StockIssuanceCostsInAccruedExpenses
152000
aplt Stock Issuance Costs In Accrued Expenses
StockIssuanceCostsInAccruedExpenses
8000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
Certain reclassifications have been made to prior period financial statements to conform to the current period presentation.
us-gaap Profit Loss
ProfitLoss
-82100000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-430900000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37500000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and reliance on third-party manufacturers.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the Company's ability to continue as a going concern as of the date of the financial statements and the reported amounts of expenses during the reporting period. In preparing the financial statements, management used estimates in the following areas, among others: prepaid and accrued expenses; warrant liabilities valuation; stock-based compensation expense; and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern.<span style="background:#ffffff;"> </span>Actual results could differ from those estimates.</p>
CY2022Q4 aplt Clinical Holdback
ClinicalHoldback
464000
aplt Clinical Holdback Retained
ClinicalHoldbackRetained
227000
CY2023Q3 aplt Clinical Holdback
ClinicalHoldback
691000
CY2023Q3 aplt Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q4 aplt Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q3 aplt Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 aplt Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q3 aplt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
4263000
CY2022Q4 aplt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
4272000
CY2023Q3 aplt Insurance Premium Asset Current
InsurancePremiumAssetCurrent
955000
CY2022Q4 aplt Insurance Premium Asset Current
InsurancePremiumAssetCurrent
1131000
CY2023Q3 us-gaap Prepaid Rent
PrepaidRent
233000
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
99000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
112000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
71000
CY2023Q3 aplt Prepaid Commercial And Patient Advocacy
PrepaidCommercialAndPatientAdvocacy
346000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
13873000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
13923000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
13873000
CY2022Q4 aplt Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Rolling Within One Year
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxRollingWithinOneYear
50000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
13923000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
13873000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
13923000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2022Q4 aplt Prepaid Commercial And Patient Advocacy
PrepaidCommercialAndPatientAdvocacy
206000
CY2023Q3 aplt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
262000
CY2022Q4 aplt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
252000
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
23000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
23000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
837000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
674000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7031000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6728000
CY2023Q3 aplt Accrued Pre Clinical And Clinical Expenses Current
AccruedPreClinicalAndClinicalExpensesCurrent
8354000
CY2022Q4 aplt Accrued Pre Clinical And Clinical Expenses Current
AccruedPreClinicalAndClinicalExpensesCurrent
8877000
CY2023Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
775000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
622000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1032000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1218000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1196000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2301000
CY2023Q3 aplt Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
59000
CY2022Q4 aplt Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
896000
CY2023Q3 aplt Accrued Patent Expenses Current
AccruedPatentExpensesCurrent
425000
CY2022Q4 aplt Accrued Patent Expenses Current
AccruedPatentExpensesCurrent
361000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
404000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
481000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12245000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14756000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1836000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2856000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5734000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7164000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3700000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9900000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.79
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4874047
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.97
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
85619
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
84639
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
8170
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.05
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4695619
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4837000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4247076
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.11
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4192000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
448543
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.05
aplt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P7Y9M18D
CY2023Q3 aplt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue
645000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
126000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
126000
us-gaap Operating Lease Cost
OperatingLeaseCost
378000
us-gaap Operating Lease Cost
OperatingLeaseCost
378000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y1M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0569
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0569
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
126000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
426000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
552000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
535000
CY2023Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2022Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42370000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-42370000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19101000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19101000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90669969
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90669969
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48000183
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48000183
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-82084000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-82084000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68079000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-68079000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75482234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75482234
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33785386
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33785386
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.02

Files In Submission

Name View Source Status
0001558370-23-018422-index-headers.html Edgar Link pending
0001558370-23-018422-index.html Edgar Link pending
0001558370-23-018422.txt Edgar Link pending
0001558370-23-018422-xbrl.zip Edgar Link pending
aplt-20230930.xsd Edgar Link pending
aplt-20230930x10q.htm Edgar Link pending
aplt-20230930xex31d1.htm Edgar Link pending
aplt-20230930xex31d2.htm Edgar Link pending
aplt-20230930xex32d1.htm Edgar Link pending
aplt-20230930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
aplt-20230930_cal.xml Edgar Link unprocessable
aplt-20230930_def.xml Edgar Link unprocessable
aplt-20230930_pre.xml Edgar Link unprocessable
aplt-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aplt-20230930x10q_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending